TY - JOUR
T1 - Management and Outcome of Acute Ischemic Stroke Complicating Transcatheter Aortic Valve Replacement
AU - ASTRO-TAVI Study Group
AU - Levi, Amos
AU - Linder, Matthias
AU - Seiffert, Moritz
AU - Witberg, Guy
AU - Pilgrim, Thomas
AU - Tomii, Daijiro
AU - Talmor-Barkan, Yeela
AU - Van Mieghem, Nicolas M.
AU - Adrichem, Rik
AU - Codner, Pablo
AU - Smith, David Hildick
AU - Arunothayaraj, Sandeep
AU - Perl, Leor
AU - Finkelstein, Ariel
AU - Loewenstein, Itamar
AU - Findler, Michael
AU - Søndergaard, Lars
AU - De Backer, Ole
AU - Wang, Christina
AU - Barnea, Rani
AU - Tarantini, Giuseppe
AU - Fovino, Luca Nai
AU - Vaknin-Assa, Hana
AU - Mylotte, Darren
AU - Lunardi, Mattia
AU - Raphaeli, Guy
AU - Webb, John G.
AU - Akodad, Mariama
AU - Colombo, Antonio
AU - Mangieri, Antonio
AU - Latib, Azeem
AU - Kargoli, Faraj
AU - Giannini, Francesco
AU - Ielasi, Alfonso
AU - Cockburn, James
AU - Higgen, Focko L.
AU - Aviram, Itay
AU - Gitto, Mauro
AU - Hokken, Thijmen W.
AU - Auriel, Eitan
AU - Kornowski, Ran
N1 - Funding Information:
Dr Pilgrim has received research grants to the institution from Edwards Lifesciences, Boston Scientific, and Biotronik; has received personal fees from Biotronik and Boston Scientific; has received other compensation from HighLife SAS and Medira; and is a proctor for Medtronic. Dr De Backer has received research grants and consulting fees from Abbott and Boston Scientific. Dr Søndergaard has received consulting fees and institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Van Mieghem has received research grant support from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, PulseCath BV, and Daiichi Sankyo; and has received advisory fees from Abbott, Boston Scientific, Ancora, Medtronic, PulseCath BV, and Daiichi Sankyo. Dr Webb has been a consultant to and has received research funding from Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Cockburn is a proctor for Boston Scientific. Dr Seiffert has served as a consultant for JenaValve and Boston Scientific; has received travel compensation from Edwards Lifesciences, JenaValve, Boston Scientific, and Biotronik; and has received speaker honoraria from Medtronic. Dr Mangieri has received a research grant (to the institution) from Boston Scientific; and has served on a medical advisory board for Boston Scientific. Dr Latib has served on advisory boards for Medtronic and Abbott; and has been a consultant to Edwards Lifesciences. Dr Akodad has received research funding from Medtronic, Biotronik, MUSE Explore, and Federation Française de Cardiologie. Dr Perl is a consultant for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2022
PY - 2022/9/26
Y1 - 2022/9/26
N2 - Background: Despite advances in transcatheter aortic valve replacement (TAVR), periprocedural acute ischemic stroke remains a concern. Objectives: The aims of this study were to investigate acute ischemic stroke complicating TAVR (AISCT) and to describe the indications and outcomes of interventions to treat AISCT. Methods: An international multicenter registry was established focusing on AISCT within 30 days of TAVR. Stroke severity was assessed using the National Institutes of Health Stroke Scale. Primary outcomes were 1-year all-cause death and neurologic disability status at 90 days according to modified Rankin scale score. Results: Of 16,615 TAVR procedures, 387 patients with AISCT were included (2.3%). Rates of 1-year death were 28.9%, 35.9%, and 77.5% in patients with mild, moderate, and severe stroke, respectively (P < 0.001). Although 348 patients were managed conservatively, 39 patients (10.1%) underwent neurointervention (NI) with either mechanical thrombectomy (n = 26) or thrombolytic therapy (n = 13). In a subanalysis excluding patients with mild stroke, there was no clear 1-year survival benefit for NI compared with conservative management (47.6% vs 41.1%, respectively; P = 0.78). In a logistic regression model controlling for stroke severity, NI was associated with 2.9-fold odds (95% CI: 1.2-7.0; P = 0.016) of independent survival at 90 days. Conclusions: AISCT carries significant morbidity and mortality, which is correlated with stroke severity. The present findings suggest that neurologic disability for patients with moderate or worse stroke could potentially be improved by timely intervention and highlight the importance of collaboration between cardiologists and neurologists to optimize AISCT outcomes.
AB - Background: Despite advances in transcatheter aortic valve replacement (TAVR), periprocedural acute ischemic stroke remains a concern. Objectives: The aims of this study were to investigate acute ischemic stroke complicating TAVR (AISCT) and to describe the indications and outcomes of interventions to treat AISCT. Methods: An international multicenter registry was established focusing on AISCT within 30 days of TAVR. Stroke severity was assessed using the National Institutes of Health Stroke Scale. Primary outcomes were 1-year all-cause death and neurologic disability status at 90 days according to modified Rankin scale score. Results: Of 16,615 TAVR procedures, 387 patients with AISCT were included (2.3%). Rates of 1-year death were 28.9%, 35.9%, and 77.5% in patients with mild, moderate, and severe stroke, respectively (P < 0.001). Although 348 patients were managed conservatively, 39 patients (10.1%) underwent neurointervention (NI) with either mechanical thrombectomy (n = 26) or thrombolytic therapy (n = 13). In a subanalysis excluding patients with mild stroke, there was no clear 1-year survival benefit for NI compared with conservative management (47.6% vs 41.1%, respectively; P = 0.78). In a logistic regression model controlling for stroke severity, NI was associated with 2.9-fold odds (95% CI: 1.2-7.0; P = 0.016) of independent survival at 90 days. Conclusions: AISCT carries significant morbidity and mortality, which is correlated with stroke severity. The present findings suggest that neurologic disability for patients with moderate or worse stroke could potentially be improved by timely intervention and highlight the importance of collaboration between cardiologists and neurologists to optimize AISCT outcomes.
KW - complications
KW - neurointervention
KW - registry
KW - thrombectomy
KW - thrombolysis
KW - transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85137718904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137718904&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2022.06.033
DO - 10.1016/j.jcin.2022.06.033
M3 - Article
C2 - 36137683
AN - SCOPUS:85137718904
VL - 15
SP - 1808
EP - 1819
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
SN - 1936-8798
IS - 18
ER -